|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Tumor category** | **Control F1****(25 mice)** | **Utx F1****(22 mice)** | **Utx F2.cKO****(40 mice)** | **Utx F2.controlA****(13 mice)** | **Utx F2.controlB****(19 mice)** | **Utx F2.control(A+B)****(32 mice)** |
| **All tumors** | 6 (0.24) | 21 (0.95) | 52 (1.30) | 8 (0.62) | 3 (0.16) | 11 (0.34) |
| **All blood tumors** | 2 (0.08) | 8 (0.36) | 9 (0.23) | 2 (0.15) | 0 | 2 (0.06) |
|  Histiocytic sarcoma | 1 (0.04) | 6 (0.27) | 6 (0.15) | 1 (0.08) | 0 | 1 (0.03) |
|  Lymphoma | 1 (0.04) | 2 (0.09) | 3 (0.08) | 1 (0.08) | 0 | 1 (0.03) |
| **All solid tumors** | 4 (0.16) | 13 (0.59) | 43 (1.08) | 6 (0.46) | 3 (0.16) | 9 (0.28) |
| **Benign solid tumors** | 2 (0.08) | 11 (0.50) | 21 (0.53) | 4 (0.31) | 3 (0.16) | 7 (0.22) |
|  Adrenocortical adenoma | 0 | 0 | 2 (0.05) | 0 | 0 | 0 |
|  Bronchial papilloma | 0 | 2 (0.09) | 0 | 0 | 1 (0.05) | 1 (0.03) |
|  Harderian adenoma | 0 | 1 (0.05) | 1 (0.03) | 1 (0.08) | 0 | 1 (0.03) |
|  Hepatocellular adenoma | 2 (0.08) | 2 (0.09) | 7 (0.18) | 2 (0.15) | 2 (0.11) | 4 (0.13) |
|  Lung adenoma | 0 | 4 (0.18) | 9 (0.23) | 1 (0.08) | 0 | 1 (0.03) |
|  Osteoma | 0 | 1 (0.05) | 1 (0.03) | 0 | 0 | 0 |
|  Pancreatic endocrine adenoma | 0 | 0 | 1 (0.03) | 0 | 0 | 0 |
|  Pancreatic exocrine adenoma  | 0 | 1 (0.05) | 0 | 0 | 0 | 0 |
| **Malignant solid tumors** | 2 (0.08) | 2 (0.09) | 22 (0.55) | 2 (0.15) | 0 | 2 (0.06) |
|  Angiosarcoma | 1 (0.04) | 0 | 2 (0.05) | 2 (0.15) | 0 | 2 (0.06) |
|  Cholangiocarcinoma | 0 | 0 | 3 (0.08) | 0 | 0 | 0 |
|  Colon adenocarcinoma | 0 | 0 | 1 (0.03) | 0 | 0 | 0 |
|  Harderian adenocarcinoma | 0 | 0 | 1 (0.03) | 0 | 0 | 0 |
|  Hepatocellular carcinoma | 1 (0.04) | 1 (0.05) | 11 (0.28) | 0 | 0 | 0 |
|  Lung adenocarcinoma | 0 | 1 (0.05) | 3 (0.08) | 0 | 0 | 0 |
|  Rhabdomyosarcoma | 0 | 0 | 1 (0.03) | 0 | 0 | 0 |